Form 4 for OFIX Orthofix Medical Inc.
Accepted 2023-06-21 00:00:00 ET · period of report 2023-06-19 · accession 0001209191-23-038789 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-21 | 2023-06-19 | OFIX | BURZIK CATHERINE M | Dir | A - Grant | $0.00 | +3,589 | 37.9K | +10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-19 | A | A | 3,589 | $0.00 | 37,949 | D | — | — | (F1) Represents an award of deferred stock units that vest in full on the earlier of (i) June 30, 2024 or (ii) the date on which the issuer holds its 2024 annual meeting of stockholders, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer. (F2) Includes 32,763 deferred stock units. (F3) Includes 1,304 shares purchased by the reporting person, on April 30, 2023, under the Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan, in a transaction exempt under Rule 16b-3(c). |